Association between LDL-C/HDL-C Ratio and Carotid Atherosclerosis in an Asymptomatic Japanese Population: A Cross-Sectional Study
Source : https://europepmc.org/article/ppr/ppr411122
Background: and aims LDL-C/HDL-C ratio predicted atherosclerosis progression better than LDL-C or HDL-C alone. However, the association between LDL-C/HDL-C ratio and Carotid Atherosclerosis(CA) is still controversial. There is a lack...
Conclusions: In conclusion, LDL-C/HDL-C ratio is an independent risk factor for CA in the Japanese population. A prospective and randomized clinical trial of LDL-C/HDL-C ratio lowering therapy in the Japanese population is needed to assess the causal nature of the relationship.
Share
A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors
Source : https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c01599
Proprotein convertase subtilisin-like/kexin type 9 (PCSK9) is a key regulator of plasma LDL-cholesterol (LDL-C) and a clinically validated target for the treatment of hypercholesterolemia and coronary artery disease. Starting from...
We demonstrated target engagement and LDL lowering in cynomolgus monkeys essentially identical to those observed with the clinically approved, parenterally dosed antibodies. These molecules represent the first report of highly potent and orally bioavailable macrocyclic peptide PCSK9 inhibitors with overall profiles favorable for potential...
Share
Conclusions: Baseline cholesterol markers can predict early infarct recurrence in patients with symptomatic ICAD. More intensive and rapid lipid lowering drugs may be required to reduce risk of early recurrence.
Share
The Priority of Non-HDL-C Assessment to Predict New Lesions among Stable Angina Patients with Strong Statins - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34039817/
Non-HDL-C ≥ 100 mg/dL was determined to be the independent risk factor for the occurrence of new lesions 9 months and ≤ 2 years after PCI among stable angina patients...
Share
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia
Source : https://www.nice.org.uk/guidance/ta733/documents/html-content-2
The Appraisal Committee has prepared a Final Appraisal Document (FAD) on Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia and submitted it to NICE. The FAD has been sent to...
Share